Samrat Pharmachem Limited

Total Valuation

Samrat Pharmachem Limited carries a market capitalization of 885.51M, placing it among publicly traded companies globally. Its enterprise value stands at 645.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Samrat Pharmachem Limited currently has 3.09M shares outstanding.

Valuation Ratios

Samrat Pharmachem Limited trades at a trailing price-to-earnings ratio of 80.47. The price-to-sales ratio is 0.21, and the price-to-book ratio stands at 19.49.

Enterprise Valuation

On an enterprise value basis, Samrat Pharmachem Limited trades at an EV/EBITDA multiple of 39.74 and an EV/FCF ratio of 60.82. The EV/Sales ratio of 0.22 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 39.74 provides insight into valuation relative to core operating earnings.

Financial Position

Samrat Pharmachem Limited maintains a current ratio of 1.86, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.70, indicating elevated leverage, while an interest coverage ratio of -2.99 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Samrat Pharmachem Limited has paid 3.31M in income taxes, reflecting an effective tax rate of 210.15.

Stock Price Statistics

Samrat Pharmachem Limited's stock has declined approximately -24.07947% over the past 52 weeks. The 50-day moving average sits at 213.89, while the 200-day moving average is 236.23.

Income Statement

Over the trailing twelve months, Samrat Pharmachem Limited generated 2.90B in revenue and converted that into -33.12M in net income, yielding earnings per share of -10.72. EBITDA reached -28.59M, while operating income came in at -28.59M.

Balance Sheet

Samrat Pharmachem Limited holds 63.82M in cash and equivalents against 107.07M in total debt, resulting in a net debt position of 48.25M. Total book value stands at 30.90M, with working capital of 479.62M providing operational flexibility.

Margins

Samrat Pharmachem Limited operates with a gross margin of 2.30, reflecting its pricing power and cost economics. The operating margin of -0.99 and net profit margin of -1.14 provide insight into operational efficiency.

Scores

Samrat Pharmachem Limited posts an Altman Z-Score of 3.36, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.